CTX310: What the First Human Results Mean for Cholesterol

Summary

CTX310 is an investigational, one-time intravenous CRISPR-Cas9 gene-editing infusion. It is not an approved cholesterol treatment and is not a routine clinical injection.

What the first human study found

In an open-label phase 1 study without a control group, 15 adults with refractory dyslipidemias received CTX310. At 0.8 mg/kg, the four-person cohort had mean day-60 changes of −48.9% in LDL cholesterol and −55.2% in triglycerides. Read the primary NEJM paper for the complete data.

Important limitations

The small, early study cannot establish long-term safety, cardiovascular-outcome benefits, or replacement of current therapies. No dose-limiting toxicities attributed to CTX310 were reported, but follow-up is continuing.